Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug ...

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...

About Traws Pharma, Inc. Antiviral Program Traws Pharma is a clinical stage biopharmaceutical company developing potential oral small molecule therapies for the treatment of respiratory viral ...

Get the detailed quarterly/annual income statement for Traws Pharma, Inc. (TRAW). Find out the revenue, expenses and profit or loss over the last fiscal year.

Traws Pharma, Inc. reported positive topline results from studies involving ferrets treated with tivoxavir marboxil for H5N1 bird flu, indicating significant suppression of disease and reduced ...

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update May 16, 2024 9:29 AM ET Traws Pharma, Inc. (TRAW) Q1: 2024-05-15 Earnings Summary ...

Traws Pharma, Inc. Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member. Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO ...

Traws Pharma Contact: Nora Brennan Traws Pharma, Inc. [email protected] www.trawspharma.com. Investor Contact: John Fraunces LifeSci Advisors, LLC 917-355-2395 [email protected].

Completed acquisition of Trawsfynydd and concurrent $14 million Capital RaiseExcellent pipeline progress, led by candidates for COVID 19, influenz ...

Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases.